Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Endocrinology

Symptoms and Warning Signs of AGL

At a Glance

The primary symptom of Acquired Generalized Lipodystrophy (AGL) is the severe loss of subcutaneous fat, typically starting in the face and neck. This lack of fat storage causes hidden metabolic symptoms, including severe insulin resistance, extremely high triglycerides, fatty liver, and extreme hunger.

Identifying the signs of Acquired Generalized Lipodystrophy (AGL) requires looking at both the visible changes on the outside of your body and the “invisible” changes occurring in your blood and internal organs.

It is crucial to distinguish between typical “weight loss” and lipoatrophy (the medical term for the loss of fat tissue). In general weight loss, you lose both fat and muscle mass, often due to diet or illness. In AGL, your body specifically destroys the subcutaneous adipose tissue (the fat layer under your skin), while your muscles often remain or even appear more prominent [1][2].

Visible Warning Signs

The most striking symptom of AGL is the progressive and near-total loss of body fat. This often follows a specific physical pattern:

  • The Pattern of Loss: The loss typically begins in the face and neck, then moves to the arms, legs, and trunk [3][2]. In female patients, this often includes a noticeable loss of breast tissue. This can lead to a “haggard” facial appearance and a very muscular or “veiny” look in the limbs as the protective fat layer disappears [1].
  • Panniculitis (Skin Nodules): For some, fat loss is preceded by panniculitis. These are painful, red, or warm nodules (lumps) under the skin [1][4]. When these inflamed lumps resolve, they often leave behind a “dent” or a permanent loss of fat in that specific area [1].
  • Acanthosis Nigricans: You may notice patches of dark, velvety skin, typically in the folds of the neck, armpits, or groin. This is a visible sign of severe insulin resistance [5].

Invisible Metabolic Signs

While the external changes are distressing, the most serious symptoms of AGL happen internally. Because your body has no place to safely store fat, it begins to overflow into your bloodstream and organs.

Symptom What it Means Impact [Citations]
Severe Insulin Resistance Your body’s cells “ignore” insulin, the hormone that manages sugar. Results in diabetes that is very difficult to control, even with massive doses of insulin [3][5].
Extreme Hypertriglyceridemia Very high levels of fat (triglycerides) in the blood. Risk for acute pancreatitis (painful pancreas inflammation) becomes significant when levels cross 500 to 1,000 mg/dL, and in AGL, levels can sometimes exceed 3,000 mg/dL (normal is <150) [6][7].
Hepatic Steatosis “Fatty liver” caused by fat storing itself inside liver cells. Can progress to steatohepatitis (inflammation) and eventually cirrhosis (scarring) [3][8].
Hyperphagia An intense, unrelenting drive to eat. Caused by the lack of leptin, the hormone that tells your brain you are full [9][10].

Why Lab Results Look Different

Your doctor may notice that while you look very thin, your blood work resembles that of someone with severe obesity. This paradox is a hallmark of AGL. In a healthy person, fat tissue acts as a “buffer” for energy; without it, your metabolic system is constantly overwhelmed [11].

A key diagnostic tool is measuring your serum leptin. In AGL, leptin levels are typically extremely low—often near zero—because there is no fat tissue left to produce it [9]. This is a major differentiator from other conditions like anorexia, where leptin levels may be low but are still generally higher than those found in AGL [9].

Monitoring these “invisible” signs through regular blood work and liver imaging is essential for preventing long-term damage to your organs [7].

Common questions in this guide

How is AGL fat loss different from normal weight loss?
In typical weight loss, you lose both fat and muscle mass. In AGL, your body specifically destroys the fat layer under the skin, a process called lipoatrophy, while your muscles remain intact and often appear more prominent.
What is panniculitis and how does it relate to AGL?
Panniculitis refers to painful, red, or warm nodules under the skin. In some patients with AGL, these inflamed lumps appear before the fat disappears, eventually leaving behind a dent or a permanent loss of fat in that specific area.
Why do I feel extremely hungry with Acquired Generalized Lipodystrophy?
Extreme hunger, known as hyperphagia, is caused by very low levels of leptin. Leptin is a hormone produced by fat tissue that tells your brain you are full, and its absence drives an unrelenting appetite.
Why does AGL cause severe insulin resistance?
Because the body has no fat tissue to safely store energy, fat overflows into the blood and organs. This overload causes your cells to stop responding to insulin properly, leading to severe insulin resistance and diabetes that is very difficult to manage.
How do leptin levels help diagnose Acquired Generalized Lipodystrophy?
Leptin is a hormone exclusively produced by fat tissue. Because AGL destroys body fat, serum leptin levels drop to extremely low or near-zero levels. This unique marker helps doctors distinguish AGL from other conditions that cause severe weight loss, like anorexia.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my labs, how severe is my insulin resistance, and what doses of insulin are typically needed for someone with my profile?
  2. 2.Do I have signs of panniculitis, and could this explain the pattern of my fat loss?
  3. 3.What is my risk for acute pancreatitis given my current triglyceride levels?
  4. 4.Have we screened for hepatic steatosis (fatty liver) or cirrhosis using imaging or specialized blood tests?
  5. 5.How do my low leptin levels distinguish my condition from other types of weight loss?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    An unusual case of acquired generalized lipodystrophy (panniculitis variety).

    Hill M, Weissman AS, Hirshburg J, et al.

    Pediatric dermatology 2024; (41(6)):1152-1155 doi:10.1111/pde.15668.

    PMID: 38887123
  2. 2

    Orbital Inflammatory Disease as a Presenting Symptom of Generalized Lipodystrophy in a Young Female.

    Shabto JM, Shteyman AR, Stevens S, et al.

    Ophthalmic plastic and reconstructive surgery 2025; (41(2)):e54-e56 doi:10.1097/IOP.0000000000002823.

    PMID: 39560295
  3. 3

    Fatty Liver and Autoimmune Hepatitis: Two Forms of Liver Involvement in Lipodystrophies.

    Ribeiro A, Brandão JR, Cleto E, et al.

    GE Portuguese journal of gastroenterology 2019; (26(5)):362-369 doi:10.1159/000495767.

    PMID: 31559327
  4. 4

    Corticosteroid-triggered acute skeletal muscle loss in lipodystrophy: A case report.

    Sasako T, Suzuki K, Odawara S, et al.

    Journal of diabetes investigation 2024; (15(6)):782-785 doi:10.1111/jdi.14158.

    PMID: 38372649
  5. 5

    Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association.

    Kumar R, Pilania RK, Bhatia A, Dayal D

    BMJ case reports 2018; (2018()) doi:10.1136/bcr-2018-225553.

    PMID: 30076164
  6. 6

    The enigma of persistent hypertriglyceridemia: A case report.

    Dhaliwal A, Ravi S, Bains K, et al.

    Clinical case reports 2022; (10(3)):e05610 doi:10.1002/ccr3.5610.

    PMID: 35356184
  7. 7

    A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation.

    Hussain I, Patni N, Ueda M, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(3)):1005-1014 doi:10.1210/jc.2017-02078.

    PMID: 29267953
  8. 8

    Lipodystrophy Syndromes.

    Hussain I, Garg A

    Endocrinology and metabolism clinics of North America 2016; (45(4)):783-797 doi:10.1016/j.ecl.2016.06.012.

    PMID: 27823605
  9. 9

    Serum levels of adiponectin differentiate generalized lipodystrophies from anorexia nervosa.

    Ceccarini G, Pelosini C, Paoli M, et al.

    Journal of endocrinological investigation 2024; (47(8)):1881-1886 doi:10.1007/s40618-024-02308-3.

    PMID: 38358463
  10. 10

    Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.

    Tchang BG, Shukla AP, Aronne LJ

    Expert opinion on biological therapy 2015; (15(7)):1061-75 doi:10.1517/14712598.2015.1052789.

    PMID: 26063386
  11. 11

    Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.

    Brown RJ, Valencia A, Startzell M, et al.

    The Journal of clinical investigation 2018; (128(8)):3504-3516.

    PMID: 29723161

This page provides information on the symptoms of Acquired Generalized Lipodystrophy (AGL) for educational purposes only. Always consult an endocrinologist or healthcare provider for an accurate medical diagnosis and personalized advice.

Get notified when new evidence is published on Acquired generalized lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.